Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Maxime Tenon"'
Autor:
Sebastian Spindeldreher, Anette Karle, Evelyne Correia, Maxime Tenon, Sascha Gottlieb, Thomas Huber, Bernard Maillere, Frank Kolbinger
Publikováno v:
mAbs, Vol 12, Iss 1 (2020)
Secukinumab, a human monoclonal antibody that selectively neutralizes IL-17A, has consistently shown low anti-drug antibody responses in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis. Secukinumab has also shown lower in vit
Externí odkaz:
https://doaj.org/article/0f77ce827ea54bc9b697edd19df709eb
Publikováno v:
Toxins, Vol 10, Iss 10, p 418 (2018)
Proliferation of Phormidium biofilms in rivers is becoming a worldwide sanitation problem for humans and animals, due to the ability of these bacteria to produce anatoxins. To better understand the environmental conditions that favor the development
Externí odkaz:
https://doaj.org/article/ea1d153a33824141856c05e321cc9f15
Autor:
Arsène Mekinian, Florent Malard, Maxime Tenon, Caroline Deswarte, Laetitia Largeaud, Olivier Fain, Sébastien Rivière, Laure Ricard, François Delhommeau, Béatrice Gaugler, on behalf Minhemon, Vincent Jachiet, Mohamad Mohty, Frédéric de Vassoigne, Pierre Hirsch, Julien Rossignol
Publikováno v:
Rheumatology. 59:3499-3504
Objectives SSc is an autoimmune disease characterized by fibrosis, microangiopathy and immune dysfunctions including dysregulation of proinflammatory cytokines. Clonal haematopoiesis of indeterminate potential (CHIP) is defined by the acquisition of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b0f9ba6408236f17f0d2eaee2d3adef
https://doi.org/10.1093/rheumatology/keaa282
https://doi.org/10.1093/rheumatology/keaa282
Autor:
Thomas Huber, Frank Kolbinger, Maxime Tenon, Evelyne Correia, Bernard Maillere, Sebastian Spindeldreher, Anette Karle, Sascha Gottlieb
Publikováno v:
mAbs
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Secukinumab, a human monoclonal antibody that selectively neutralizes IL-17A, has consistently shown low anti-drug antibody responses in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis. Secukinumab has also shown lower in vit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fb91c766ab92347bf9d19c15152f4b1
http://europepmc.org/articles/PMC8648323
http://europepmc.org/articles/PMC8648323
Autor:
Maxime Tenon, Frank Kolbinger, Bernard Maillere, Philip Jarvis, Anette Karle, Evelyne Correia, Sebastian Spindeldreher
Publikováno v:
Dermatology and Therapy
Introduction Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has been shown to have significant efficacy in the treatment of moderate to severe plaque psoriasis (PsO) and psoriatic arthritis (PsA), demonstrating a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb63f0671c55c3b4c9f8d98aea80aa9e
https://doi.org/10.1007/s13555-018-0220-y
https://doi.org/10.1007/s13555-018-0220-y
Publikováno v:
Toxins
Toxins, MDPI, 2018, 10 (10), pp.418. ⟨10.3390/toxins10100418⟩
Volume 10
Issue 10
Toxins, Vol 10, Iss 10, p 418 (2018)
Toxins 10 (10), 1-14. (2018)
Toxins, MDPI, 2018, 10 (10), pp.418. ⟨10.3390/toxins10100418⟩
Volume 10
Issue 10
Toxins, Vol 10, Iss 10, p 418 (2018)
Toxins 10 (10), 1-14. (2018)
International audience; Proliferation of Phormidium biofilms in rivers is becoming a worldwide sanitation problem for humans and animals, due to the ability of these bacteria to produce anatoxins. To better understand the environmental conditions tha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a117774dc742320e28688f6675835c5
http://europepmc.org/articles/PMC6215143
http://europepmc.org/articles/PMC6215143
Autor:
Evelyne Correia, Frank Kolbinger, Sebastian Spindeldreher, Maxime Tenon, Bernard Maillere, Philip Jarvis, Anette Karle
Publikováno v:
Journal of the American Academy of Dermatology. 79:AB256
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1ee1746d1e2802606621cb4c2c7c5f11
https://doi.org/10.1016/j.jaad.2018.05.1017
https://doi.org/10.1016/j.jaad.2018.05.1017
Autor:
Bernard Maillere, Frank Kolbinger, Philip Jarvis, Evelyne Correia, Maxime Tenon, Sebastian Spindeldreher, Anette Karle
Publikováno v:
Dermatology and Therapy. 8:327-327
In the original publication, information regarding “ustekinumab” was incorrectly published under the Methods section. The correct information in the section “Antibodies and Control Protein” should be “(secukinumab, 150 mg/mL; ixekizumab, 90
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ec7aa7664492d7fb1f2a781f2712cf56
https://doi.org/10.1007/s13555-018-0234-5
https://doi.org/10.1007/s13555-018-0234-5